Clinical trials: Olaparib
Cancer
Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but life-threatening adverse events such as myelodysplastic syndrome (MDS) and/or acute myeloid…
- Trial name
- NCT04326023
- Testing
- PARP Inhibitors
- Where
- France
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Breast Cancer
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual…
- Trial name
- NCT05677308
- Where
- 38 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Sarcoma, Sarcoma Metastatic
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body.
- Trial name
- NCT04076579
- Testing
- Olaparib, Trabectedin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Prostate Cancer
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites.
- Trial name
- NCT04560452
- Where
- 37 sites in China
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Cancer
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
This study is looking at outcomes in people with advanced cancers who have exhausted standard treatment options and are accessing off indication or unregistered drugs or combinations of drugs through compassionate access from the…
- Trial name
- TAILOR (NCT04801966)
- Testing
- Trametinib, Cobimetinib, Binimetinib
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Bowel Obstruction, Ovarian Cancer
Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer
Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal.
- Conditions
- Bowel Obstruction, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- CEBOC (NCT07648745)
- Testing
- Cediranib
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Prof Gordon Jayson
Germ Cell Cancer
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
The goal of this clinical research study is to find the highest safe dose of olaparib that can be combined with chemotherapy drugs and stem cell transplantation to treat patients with relapsed and refractory germ cell cancer.
- Trial name
- NCT07850973
- Testing
- Olaparib, Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Pediatric Cancer
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019).
- Trial name
- ESMART (NCT02813135)
- Testing
- Ribociclib, Topotecan, Temozolomide
- Where
- 23 sites in Denmark, France and 4 more
- Volunteers
- 472 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer
Lynparza Breast Cancer Clinical Experience Investigation
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Trial name
- NCT03590938
- Where
- 31 sites in Japan
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first…
- Conditions
- Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04394858
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging
- Where
- 163 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce.
- Trial name
- NCT04774627
- Testing
- PARP inhibitor
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Caen
Solid Tumours
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.
- Trial name
- NCT04236414
- Testing
- Olaparib
- Where
- 10 sites in Denmark, France and 4 more
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin, Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a…
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- TAPUR (NCT02693535)
- Testing
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Where
- 181 sites in United States, Puerto Rico
- Volunteers
- 4,200 people
- Sponsor
- American Society of Clinical Oncology
Ovarian Cancer
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
The trial will compare the drugs olaparib and cediranib with standard chemotherapy in platinum resistant ovarian cancer. Patients will be randomised to one of three treatment groups: olaparib only, olaparib and cediranib and the…
- Trial name
- OCTOVA (NCT03117933)
- Testing
- Olaparib, Cediranib, Paclitaxel
- Where
- 14 sites in United Kingdom
- Volunteers
- 139 people
- Sponsor
- University of Oxford
Cancer
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce.
- Trial name
- NCT04774406
- Testing
- olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
- Where
- France
- Volunteers
- 2,336 people
- Sponsor
- University Hospital, Caen
Endometrial Cancer
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug under the…
- Trial name
- NCT06995833
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.
Ovarian cancer is the second fatal gynecological cancer. More than 70% of ovarian cancer patients are diagnosed as advanced. Olaparib is the first oral poly adenosine diphosphate-ribose polymerase inhibitor (PAPPi) approved by…
- Trial name
- NCT04699006
- Where
- China
- Volunteers
- 245 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University